CARLSBAD, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Greenwich Biosciences, U.S. subsidiary of GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, ...
COPENHAGEN — A cannabis extract reduces spasticity and is safe in patients with motor neuron diseases (MND), including amyotrophic lateral sclerosis (ALS), results of the phase 2 randomized ...
Porton Down, UK, 12 October 2012: GW Pharmaceuticals (AIM: GWP) is pleased to announce that results of the MObility ImproVEments with Spasticity in Multiple Sclerosis (MOVE) 2 observational study ...
Porton Down, UK, 12 October 2012: GW Pharmaceuticals (AIM: GWP) is pleased to announce that results of the MObility ImproVEments with Spasticity in Multiple Sclerosis (MOVE) 2 observational study ...
- Results from analysis of three Phase 3 clinical studies showed statistically significant improvement in spasticity in people with multiple sclerosis - Treatment with nabiximols seen in this analysis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback